Results 1 to 10 of about 27,299 (305)

Cutaneous polyarteritis nodosa [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2015
Polyarteritis nodosa is a rare vasculitis in children characterized by necrotizing inflammation in small and medium size arteries. It is classified into systemic and cutaneous PAN according to the presence of systemic symptoms or visceral involvement. We
María Alejandra Matteoda   +5 more
doaj   +10 more sources

Polyarteritis Nodosa: Old Disease, New Etiologies. [PDF]

open access: yesInt J Mol Sci, 2023
Polyarteritis nodosa (PAN), also known as panarteritis nodosa, represents a form of necrotizing vasculitis that predominantly affects medium-sized vessels, although it is not restricted to them and can also involve smaller vessels.
Wolff L   +4 more
europepmc   +2 more sources

Cutaneous polyarteritis nodosa [PDF]

open access: yesBritish Journal of Dermatology, 2002
Classic polyarteritis nodosa (PAN) is a segmentary leucocytoclastic vasculitis that affects small- and medium-sized arteries. In 1931, Lindberg (Acta Med Scand 1931; 76: 183-225) described the existence of a cutaneous variant of PAN, without visceral ...
Bauza, A. (Ana)   +2 more
core   +5 more sources

Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare [PDF]

open access: yesCase Reports in Medicine, 2009
Polyarteritis nodosa (PAN) is a systemic vasculitis whose severe forms are treated with glucocorticoids and cyclophosphamide. Refractory patients are exposed to many complications, notably accelerated atherosclerosis.
Emmanuel Ribeiro   +7 more
doaj   +3 more sources

Myocarditis and intramural coronary vasculitis in polyarteritis nodosa: an unusual treatable form of heart failure [PDF]

open access: yesESC Heart Failure, 2020
We describe an uncommon cardiac presentation of polyarteritis nodosa. A 68‐year‐old woman, with a history of fatigue, weight loss, and myalgia of the lower extremities, was admitted for congestive heart failure.
Cristina Chimenti   +7 more
doaj   +2 more sources

Case Report: A case of cutaneous polyarteritis nodosa in a child following a streptococcal infection [PDF]

open access: yesFrontiers in Pediatrics
BackgroundPolyarteritis nodosa is a rare systemic necrotizing vasculitis that is often overlooked and misdiagnosed in clinical practice. Patients may exhibit fever, rash, myalgia, and further symptoms; in severe instances, this may result in damage to ...
Wei Cheng, Wei Yin, Fan Liu, Wen Yin
doaj   +2 more sources

Polyarteritis nodosa presenting with severe upper gastrointestinal bleeding: a case report [PDF]

open access: yesJournal of Medical Case Reports
Background Polyarteritis nodosa is a relatively uncommon type of systemic necrotizing vasculitis that primarily affects medium-sized arteries. While gastrointestinal involvement is known in polyarteritis nodosa, heavy gastrointestinal bleeding due to ...
Xin-Yue Xiao   +7 more
doaj   +2 more sources

A Case of Polyarteritis Nodosa Associated with Vertebral Artery Vasculitis Treated Successfully with Tocilizumab and Cyclophosphamide

open access: yesCase Reports in Pediatrics, 2016
Pediatric polyarteritis nodosa is rare systemic necrotizing arteritis involving small- and medium-sized muscular arteries characterized by aneurysmal dilatations involving the vessel wall.
Kae Watanabe   +2 more
doaj   +2 more sources

Renal infarction due to polyarteritis nodosa in a patient with angioimmunoblastic T-cell lymphoma: a case report and a brief review of the literature [PDF]

open access: yesDiagnostic Pathology, 2012
Angioimmunoblastic T-cell lymphoma is one of the most common subtypes of peripheral T-cell lymphoma (15-20% of all cases), accounting for approximately 1-2% of all non-Hodgkin lymphomas.
Ambrosio Maria   +7 more
doaj   +4 more sources

Elicitation of expert prior opinion:application to the MYPAN trial in childhood polyarteritis nodosa [PDF]

open access: yesPediatric Rheumatology Online Journal, 2015
Objectives Definitive sample sizes for clinical trials in rare diseases are usually infeasible. Bayesian methodology can be used to maximise what is learnt from clinical trials in these circumstances.
, MYPAN Vasculitis Expert Group   +15 more
core   +2 more sources

Home - About - Disclaimer - Privacy